Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse - Wikidata - wikimedia - TriplyDB

Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse

Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse

http://www.wikidata.org/entity/Q33658203

about

Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?Early phase clinical trials to identify optimal dosing and safety Phase I trials of antitumour agents: fundamental concepts Designs of drug-combination phase I trials in oncology: a systematic review of the literature Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor Is the "3+3" dose-escalation phase I clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for alternative design.Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes.Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trials Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.Phase I pharmacokinetic and pharmacodynamic evaluation of combined valproic acid/doxorubicin treatment in dogs with spontaneous cancer.Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience Adaptive designs for identifying optimal biological dose for molecularly targeted agents.PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities.N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012.Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic.Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience.PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment.Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection.Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers.Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer Treating metastatic cancer with nanotechnology.Nanomedicine: de novo design of nanodrugs.Phase 1 trial design: is 3 + 3 the best?The changing landscape of phase I trials in oncology.Determinants of the recommended phase 2 dose of molecular targeted agents.Challenges and Innovations in Phase I Dose-Finding Designs for Molecularly Targeted Agents and Cancer Immunotherapies.Seamless phase I-II trial design for assessing toxicity and efficacy for targeted agents.Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013.TEAMS: Toxicity- and Efficacy-based Dose Insertion Design with Adaptive Model Selection for Phase I/II Dose-Escalation Trials in Oncology Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center.Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns.Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 Patients.Evolution of early phase clinical trials in oncology.STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials.

P2860

Q26859144-ADE9DA13-1DC7-4AAF-9950-62A88DEE16C4 Q26865076-63A54A0E-85D1-401E-9A3B-1F73675ADC2A Q26865346-C18C4FE6-EE3F-417F-9AB2-3B9118AF8B49 Q26996348-A3E56CEF-44A1-4606-8FB7-C1541E0ACD2F Q27342948-43E659D8-889F-491A-A4DF-96BAD9ED5A1B Q30370848-27952D35-2216-4B3E-BCAA-03B010E9F01D Q33399986-634D25D7-2E3C-496F-86E7-E1204BB03B9F Q33845387-92C2C235-9358-421B-BE28-9F914D72FC4E Q33849805-27E8AEC7-C226-4AB4-A7B0-2AC39CE0D27E Q34153696-77D1610B-8E17-4FB8-9831-5C9DC3F1CBFA Q34168530-D99D9F1B-C1EA-46CA-AB6F-992B14A911C8 Q34252383-C0DE7E9B-5268-4FE6-BC67-57F425DED638 Q34550826-00D89C3C-C22E-4733-B6BB-80409CA4DA28 Q34769343-5CDD4761-1A6D-461D-B9B0-C33710C9B60C Q35104052-ACD76CF9-EA5E-4683-9A9B-A74DECC1203B Q35376207-6F689997-5F2B-4855-82C5-F2787DC55ECB Q35584482-E95BD9CD-1CAC-4CB6-BF08-83842A6F045B Q35584811-36D7E710-B5A6-4E96-8335-EEA777B117C4 Q35808438-37496A34-889A-492F-93FA-C8C8928E7DD6 Q35894574-24D34F92-699D-4084-A7B5-7E6E9E78742D Q35914787-729B6C8F-68D7-4984-A9AC-6DA397051856 Q36153295-59600D95-5BAE-4004-9BD9-24CF44730953 Q36984851-D4EB11EA-3393-4A94-91D1-39F8AEA942AB Q36998239-E5991369-BF0B-4AEB-B1A3-E37D97D883CE Q37297137-77273862-9CEB-4950-A710-0BE9785E4C0D Q37344085-E05643D7-FAE5-4EB1-9E30-D248D6B6361F Q37970910-E96C907D-5D2D-49AD-AC08-05A0F225BB05 Q38168683-38BB4ADA-4C3E-41A2-8EC7-A9F41DA3F818 Q38222466-16E4B549-35CF-42D2-9A69-BFEC55E9C10A Q38629203-C4A9891A-98A8-42F9-9223-2AFA49267ED5 Q39128248-9DB770D8-97E4-4DF3-AE83-6EFCD52E364F Q39374749-697FFE5B-C2A6-48DD-B382-638558198690 Q39449883-3AC085D7-F00C-434F-B853-076801D23ED3 Q41673963-79F35551-C111-49C8-A957-D98987CC4C66 Q42108875-18907488-7E44-4A7F-BE08-B292FE4DF66A Q43455943-D637B8A3-F584-45CF-9D31-B74F71D9792F Q44209463-49D29841-53C6-4E0C-84F5-976FC58DB6CB Q45994683-E3FCDE88-DCC2-4E77-A0D0-4E7F7867F4DF Q47816379-046FB871-494A-451E-AD35-1E802602F6BB Q48275752-C96DF3FD-4429-4578-B6B7-7F2E63FC0A7F

P2860

Phase I oncology studies: evidence that in the era of targeted therapies patients on lower doses do not fare worse

http://www.wikidata.org/entity/Q33658203

description

2010 nî lūn-bûn

@nan

2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Phase I oncology studies: evid ...... lower doses do not fare worse

@ast

Phase I oncology studies: evid ...... lower doses do not fare worse

@en

type

label

Phase I oncology studies: evid ...... lower doses do not fare worse

@ast

Phase I oncology studies: evid ...... lower doses do not fare worse

@en

prefLabel

Phase I oncology studies: evid ...... lower doses do not fare worse

@ast

Phase I oncology studies: evid ...... lower doses do not fare worse

@en

P1433

Q33658203-2012DD74-F3F2-47A4-94C8-392C228EC602

P1476

Q33658203-5EBAC358-58C5-402C-AD83-2AA434505617

P2093

Q33658203-02C3E6D9-A68C-4EA5-B478-3C7B5CEAC027

Q33658203-2AB23B0C-413D-48ED-A71D-E5502F3E37B6

Q33658203-2D557C68-E39A-489E-B9EB-A9F9645845A4

Q33658203-584FEE6E-0AD3-4BD9-8A4D-0BC8E6894A03

Q33658203-5902F198-0A7B-47D0-8A54-2F5438CD7915

Q33658203-DE9A1406-80E5-4875-ACBB-D4FEE5932D98

P2860

Q33658203-0A615C60-FC03-4D79-BD72-4A10879B3CE1

Q33658203-0DAE623B-5212-4E0A-B91A-6D301862BDD2

Q33658203-0E1CA7A1-38DF-4A6A-AB40-D39BF223438E

Q33658203-1CB8ABB1-D9F2-40AA-9CFC-559F842FB667

Q33658203-2033D307-88DA-4E94-975E-284BDAC933E6

Q33658203-237229D4-E036-4A26-99A1-A54D08950A0E

Q33658203-23C34A55-EB87-45F1-82A1-C3913BF97C64

Q33658203-3758D1C4-098A-4357-86C8-DD491A246524

Q33658203-53C1B5CF-92CD-4F1F-B38B-53D41A52141D

Q33658203-55C9788D-C87A-48B8-B7AB-3530ADC148F1

P304

Q33658203-F249981F-46C7-44DB-BA0C-0D5DA45FB2F4

P31

Q33658203-4A87D26A-77C9-4B62-B71F-9F67749868C0

P356

Q33658203-80312EF7-93BF-4B00-A6DC-5309E4B91F00

P407

Q33658203-6CCD2C8C-7744-47CA-A114-9D203EFD25EE

P433

Q33658203-C22E858B-5FF4-4EF5-9D7E-D6E9110F3141

P478

Q33658203-6E0D96E8-B248-495B-8AF8-581574F7FA71

P50

Q33658203-124168CA-85AD-4B7E-B7F8-8D389CE82FC8

Q33658203-CA23A2E2-9123-4E67-8E3E-DCF9F63F6EDA

P577

Q33658203-AFC6FCD0-7F0E-4CEA-B745-A974646BE61B

P698

Q33658203-1E25474F-FE72-45D4-AB22-809D8F95EF8D

P932

Q33658203-B44884E1-0A27-4DEB-8409-B8A6AC43F12A

P356

1078-0432.CCR-09-2684

P1433

Clinical Cancer Research

P1476

Phase I oncology studies: evid ...... lower doses do not fare worse

@en

P2093

David Hong

http://www.w3.org/2001/XMLSchema#string

J Jack Lee

http://www.w3.org/2001/XMLSchema#string

Jennifer Wheler

http://www.w3.org/2001/XMLSchema#string

Jing Gong

http://www.w3.org/2001/XMLSchema#string

Maurie Markman

http://www.w3.org/2001/XMLSchema#string

Rajul K Jain

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Dose-response effect of adjuvant chemotherapy in breast cancer

Reporting results of cancer treatment

Ethical issues in the development of new agents.

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients.

Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies

The design of clinical trials for new molecularly targeted compounds: progress and new initiatives.

Clinical trial design for target-based therapy.

Clinical trial design for target specific anticancer agents.

The needs of science vs the needs of patients: ethical concerns in cancer clinical trials.

P304

1289-1297

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-09-2684

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Razelle Kurzrock

P577

2010-02-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20145187

http://www.w3.org/2001/XMLSchema#string

P932

2822881

http://www.w3.org/2001/XMLSchema#string